What is SafeHeal?
SafeHeal specializes in the development of Colovac, a sophisticated, fully reversible flexible bypass sheath. Invented by French digestive surgeon Dr. Charam Khosrovani, the device is engineered to prevent fecal contact at the anastomotic level following colorectal procedures. By eliminating the necessity for a digestive ostomy, the technology significantly enhances patient quality of life, allowing for a seamless recovery process without the long-term burden of a stoma. The company's commitment to clinical excellence and patient-centric design has positioned it as a critical player in the global medical device market, bridging the gap between complex surgical requirements and improved post-operative outcomes.
How much funding has SafeHeal raised?
SafeHeal has raised a total of $103.8M across 3 funding rounds:
Series A
$7.4M
Series B
$44.9M
Series C
$51.5M
Series A (2018): $7.4M, investors not publicly disclosed
Series B (2022): $44.9M led by Sofinnova Partners and Genesis MedTech
Series C (2025): $51.5M supported by The American Solar Eclipse, Sofinnova Partners, Gideon Strategic Partners, M&L Holdings Group, M&L Healthcare Solutions, and Asabys Partners
Key Investors in SafeHeal
Sofinnova Partners
A leading European venture capital firm in life sciences, Sofinnova Partners specializes in healthcare and sustainability, acting as a hands-on company builder from seed to later-stage investments.
Asabys Partners
Based in Barcelona, Asabys Partners focuses on fostering breakthrough innovation in healthcare and life sciences by investing in transformative technologies that improve patient outcomes.
Genesis MedTech
Headquartered in Singapore, Genesis MedTech is a specialized medical device company focused on advancing surgical solutions and healthcare technology.
What's next for SafeHeal?
With the successful closure of this major enterprise-level funding, SafeHeal is well-positioned to accelerate its clinical development and market expansion strategies. The capital will likely be deployed to scale manufacturing capabilities, support ongoing clinical trials, and broaden the commercial reach of the Colovac device across international markets. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward securing regulatory milestones and establishing long-term partnerships with healthcare providers. This strategic growth phase is expected to solidify SafeHeal's role in redefining surgical standards, ultimately driving value for both patients and stakeholders in the evolving healthcare technology ecosystem.
See full SafeHeal company page
